Does oral Ranitidine improve magnetic resonance cholangio-pancreatogram images allowing clinically useful improvement?

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2006-002702-63-GB

Enrollment

Registered

2006-12-07

Start date

2007-03-08

Completion date

Unknown

Last updated

2020-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Image quality improvement in Magnetic Resonance Cholangio-Pancreatogram scans MedDRA version: 8.1 Level: LLT Classification code 10058641 Term: Nuclear magnetic resonance imaging abdominal

Interventions

Trade Name: Ranitidine Product Name: Ranitidine Pharmaceutical Form: Tablet Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- Pharmaceutical form of the placebo:

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All MRCP requests Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Previous Gastro-duodenal and/or biliary surgery On H2 receptor blockers or Proton pump inhibitors Unfit, moribund or non-communicable

Design outcomes

Primary

Measure	Time frame
Main Objective: To assess if MR scanning is sensitive enough to be influenced by the suppression of total gastric secretions by a single dose of Ranitidine leading to the improvement of image quality of Magnetic Resonance Cholangio-Pancreatogram images to a clinically useful extent.;Secondary Objective: Does improvement in image quality of MRCP scan images influence the number of ERCP requests?;Primary end point(s): Significant improvement in image quality of MRCP scans.	—

Measure

Time frame

Main Objective: To assess if MR scanning is sensitive enough to be influenced by the suppression of total gastric secretions by a single dose of Ranitidine leading to the improvement of image quality of Magnetic Resonance Cholangio-Pancreatogram images to a clinically useful extent.;Secondary Objective: Does improvement in image quality of MRCP scan images influence the number of ERCP requests?;Primary end point(s): Significant improvement in image quality of MRCP scans.

—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026